<DOC>
	<DOCNO>NCT02873702</DOCNO>
	<brief_summary>The purpose study determine efficacy dexlansoprazole compare lansoprazole heal erosive esophagitis ( EE ) Chinese participant .</brief_summary>
	<brief_title>Efficacy Safety Dexlansoprazole Healing Maintaining Healing Erosive Esophagitis</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . Dexlansoprazole test treat people EE . This study look erosive esophageal heal people take dexlansoprazole . The study enroll approximately 450 participant . Participants randomly assign one two treatment group 1:1 ratioâ€”which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Dexlansoprazole 60 mg - Lansoprazole 30 mg After 8 week treatment , participant evaluate assess esophageal healing . If EE heal participant randomly assign one two different treatment group 1:1 ratio : - Dexlansoprazole 30 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct China . The overall time participate study 39 week . Participants make 7 visit clinic , contact telephone 5 10 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . Has endoscopically confirm EE define LA Classification Grading System ( AD ) . 1 . Participant required take exclude medication , anticipate participant require treatment least 1 disallow concomitant medication study evaluation period . 2 . Has hypersensitivity proton pump inhibitor ( PPI ) ( include , limited , lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole ilaprazole ) , component dexlansoprazole , antacid ( example , magnesium trisilicate similar antacid ) . 3 . Had history cancer , ( except basal cell carcinoma skin ) , remission least 5 year prior Screening . 4 . Has know history suspicious Barrett 's esophagus dysplastic change see screen endoscopy . 5 . Developed acute upper gastrointestinal bleeding , gastric ulcer ( mucosal defect white coating ) duodenal ulcer ( mucosal defect white coating ) , within 30 day start Screening Visit ( possible inclusion gastric duodenal erosion ) . The participant require chronic use ( &gt; 12 dos per month ) non steroidal antiinflammatory drug ( NSAIDs ) include cyclooxygenase2 ( COX2 ) NSAIDs within 30 day prior Screening Period throughout study . 6 . Has comorbidities could affect esophagus ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) ; history radiotherapy cryotherapy esophagus ; history corrosive physiochemical injury ( possible inclusion study Schatzki 's ring ) . 7 . Has history surgical procedure may affect esophagus ( example , fundoplication mechanical dilatation esophageal stricture ) history gastric duodenal surgery endoscopic removal benign polyp . 8 . Participant know acquired immunodeficiency syndrome ( AIDS ) hepatitis , include hepatitis virus carrier ( , hepatitis B surface antigen HBsantigen ( HBsAg ) positive hepatitis C virus ( HCV ) antibody positive ) . 9 . Has current ZollingerEllison syndrome ( gastric acid hyper secretion ) history gastric acid hypersecretion . 10 . Participant schedule surgery require hospitalization require surgical treatment his/her participation study . 11 . Has donate lose &gt; 300 milliliter ( mL ) blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 12 . Has history alcohol drug abuse ( define illicit drug use ) , drug addiction 12 month prior Screening . 13 . The participant positive serology result Helicobacter pylorus ( H. pylori ) need eradication therapy study participation period anticipate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>